Zensun Shanghai Science & Technology

Zensun is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of first-in-class biologics for cardiovascular, oncology, and metabolic diseases. The company's flagship candidate, Neucardin (recombinant human neuregulin-1), is a novel therapy for chronic heart failure that works by directly repairing damaged cardiomyocytes and improving cardiac function. Zensun's research is centered on the neuregulin/ErbB signaling pathway, aiming to address significant unmet medical needs in heart health. Beyond cardiovascular care, the company is expanding its pipeline to include targeted therapies for HER2-positive cancers and metabolic disorders. Zensun operates integrated R&D and manufacturing facilities to support its global clinical development programs.